A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK
Activator (2) in combination with metformin, compared to that of placebo (metformin
monotherapy), in patients with type 2 diabetes mellitus. Patients will continue on their
stable dose of metformin and will be randomized to receive either GK Activator (2) or
placebo. The anticipated time on study treatment is less than 3 months, and the target sample
size is 100-500 individuals.